WO2002043566A3 - Devices and methods for treating low blood sugar levels - Google Patents
Devices and methods for treating low blood sugar levels Download PDFInfo
- Publication number
- WO2002043566A3 WO2002043566A3 PCT/US2001/044552 US0144552W WO0243566A3 WO 2002043566 A3 WO2002043566 A3 WO 2002043566A3 US 0144552 W US0144552 W US 0144552W WO 0243566 A3 WO0243566 A3 WO 0243566A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- source
- area
- intact skin
- devices
- Prior art date
Links
- 239000008280 blood Substances 0.000 title abstract 3
- 210000004369 blood Anatomy 0.000 title abstract 3
- 102000051325 Glucagon Human genes 0.000 abstract 4
- 108060003199 Glucagon Proteins 0.000 abstract 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 4
- 229960004666 glucagon Drugs 0.000 abstract 4
- 239000008103 glucose Substances 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 235000019155 vitamin A Nutrition 0.000 abstract 1
- 239000011719 vitamin A Substances 0.000 abstract 1
- 235000019154 vitamin C Nutrition 0.000 abstract 1
- 239000011718 vitamin C Substances 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to methods and devices employed to control the onset of blood sugar levels below a predetermined minimum level over an extended period of time. The invention includes methods and devices for producing a therapeutic effect in a subject including placing a source of glucose or glucagon in a transdermal patch in transmitting relationship to an area of intact skin; and administering glucose or glucagon to the subject from the source through the area of intact skin for an extended period of time at a therapeutically effective rate for a substantial portion of the extended period of time to prevent the onset of a low blood sugar level in the subject. The methods and devices may include administering glucose or glucagon to the subject from the source through the area of intact skin for at least 4 hours, or longer, perhaps 24 hours or more, and are particularly well suited for administering glucose or glucagon to the subject from the source through the area of intact skin between usual sleeping hours. Additional therapeutic substances may also be administered to the subject from the source through the area of intact skin, including one or more nutritional supplements such as vitamins A, C, or D.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002230509A AU2002230509A1 (en) | 2000-11-28 | 2001-11-28 | Devices and methods for treating low blood sugar levels |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72383700A | 2000-11-28 | 2000-11-28 | |
| US09/723,837 | 2000-11-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002043566A2 WO2002043566A2 (en) | 2002-06-06 |
| WO2002043566A3 true WO2002043566A3 (en) | 2002-09-26 |
Family
ID=24907892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/044552 WO2002043566A2 (en) | 2000-11-28 | 2001-11-28 | Devices and methods for treating low blood sugar levels |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002230509A1 (en) |
| WO (1) | WO2002043566A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05006994A (en) | 2002-12-27 | 2005-10-18 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia. |
| US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
| US9452258B2 (en) | 2007-10-09 | 2016-09-27 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
| WO2009055736A1 (en) | 2007-10-25 | 2009-04-30 | Dexcom, Inc. | Systems and methods for processing sensor data |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234906A (en) * | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| US5360614A (en) * | 1993-04-26 | 1994-11-01 | The Estee Corporation | Method of controlling the release of carbohydrates by encapsulation and composition therefor |
| US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
-
2001
- 2001-11-28 AU AU2002230509A patent/AU2002230509A1/en not_active Abandoned
- 2001-11-28 WO PCT/US2001/044552 patent/WO2002043566A2/en not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234906A (en) * | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| US5360614A (en) * | 1993-04-26 | 1994-11-01 | The Estee Corporation | Method of controlling the release of carbohydrates by encapsulation and composition therefor |
| US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002230509A1 (en) | 2002-06-11 |
| WO2002043566A2 (en) | 2002-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL135712A0 (en) | Methods for treating hypercoagulable states or acquired protein c deficiency | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| JP2003521528A5 (en) | ||
| WO2002065985A3 (en) | Methods of treating diabetes mellitus | |
| DE60222137D1 (en) | SUGAR DERIVATIVES OF HYDROMORPHONE, DIHYDROMORPHINE AND DIHYDROISOMORPHINE, COMPOSITIONS THEREOF AND USE FOR THE PREVENTION AND TREATMENT OF PAIN | |
| WO2004052284A3 (en) | Treatment of diabetes | |
| MXPA03006217A (en) | Spaced drug delivery system. | |
| MXPA05006994A (en) | Compositions and methods for the prevention and control of insulin-induced hypoglycemia. | |
| WO2003089033A8 (en) | Implantable drug delivery system responsive to intra-cardiac pressure | |
| WO2002015920A3 (en) | Treatment of hyperproliferative diseases | |
| WO2002070473A3 (en) | Carboxamide derivatives as therapeutic agents | |
| EP1733734A3 (en) | Placental alkaline phosphatase to control diabetes | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| WO2002060410A3 (en) | Methods for sustained release local delivery of drugs for ablation of unwanted tissue | |
| WO2004010946A3 (en) | Therapeutic treatment for the metabolic syndrome and type 2 diabetes | |
| WO2002043566A3 (en) | Devices and methods for treating low blood sugar levels | |
| WO2002005801A3 (en) | Compositions containing diacyltartaric salts of (e)-metanicotine | |
| US20040157813A1 (en) | Treatment of obstructive sleep apnea | |
| WO2004060316A3 (en) | Irs modulators | |
| AU3308099A (en) | Method for the treatment of pain, including chronic and female specific pain | |
| WO2005087255A3 (en) | Method of optimizing treatment with interferon-tau | |
| EP1033133A4 (en) | Composition for treatment of diabetes and treatment of diabetes | |
| NO20005131L (en) | New treatments for nervous disorders | |
| WO2001028578A3 (en) | A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME | |
| ATE207353T1 (en) | USE OF BENZYDAMINE TO TREAT MEDICAL CONDITIONS CAUSED BY TNF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |